Antiangiogenic therapies in urogenital malignancies
نویسندگان
چکیده
منابع مشابه
Antiangiogenic therapies in urogenital malignancies
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from rena...
متن کاملAntiangiogenic therapies in ovarian cancer
Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the formation and progression of ovarian cancer. Several well-designed phase II and III trials studied the efficacy of antiangiogenic agents in advanced ovarian cancer. The results of these trials demonstrated significantly prolonged progression-free survival when antiangiogenic agents were used as a maintenance therap...
متن کاملAntiangiogenic therapies in ovarian cancer
Ovarian cancer is the fifth leading cause of cancer deaths among women and the leading cause of death from cancer of the gynecologic organs [1]. Often termed ‘the silent killer’, it usually produces no symptoms until it is in an advanced stage [2]. Few women have ovarian can‐ cer detected early and almost 75% of women diagnosed with ovarian cancer present at an advanced stage. Although the 5‐ye...
متن کاملAntiangiogenic therapies in glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most common and lethal of adult gliomas. The prognosis for the great majority of patients with GBM is poor as almost all tumors recur following optimal surgical resection, radiation and standard chemotherapy, resulting in rapid disease-related death. The standard of care for recurrent GBM has not been clearly established. GBMs are highly vascularized brain t...
متن کاملThe inefficacy of antiangiogenic therapies
In 1971, Judah Folkman published in the “New England Journal of Medicine” a hypothesis that tumor growth is angiogenesis-dependent and that inhibition of angiogenesis could be therapeutic [1]. This article also introduced the term antiangiogenesis to mean the prevention of new vessel sprouts from being recruited by a tumor. In the last 35 years, it has been estimated that > 200 companies have w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: memo - Magazine of European Medical Oncology
سال: 2017
ISSN: 1865-5041,1865-5076
DOI: 10.1007/s12254-017-0375-8